{"id":3351,"date":"2015-07-01T21:12:34","date_gmt":"2015-07-01T21:12:34","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=2871"},"modified":"2015-07-01T21:12:34","modified_gmt":"2015-07-01T21:12:34","slug":"medical-marijuana-inc-announces-investment-in-axim-biotechnologies","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2015\/07\/01\/medical-marijuana-inc-announces-investment-in-axim-biotechnologies\/","title":{"rendered":"Medical Marijuana, Inc. Announces Investment in AXIM Biotechnologies"},"content":{"rendered":"

Cutting-Edge Global Industrial Hemp-Based Biotechnology Company Brings Added Diversity in Food\u00a0and Pharmaceuticals to MJNA\u2019s Growing Investment Portfolio<\/h3>\n

Medical Marijuana, Inc. (OTC Pink: MJNA) would like to inform the public and shareholders that it holds 14,943,650 shares of common stock and 500,000 shares of preferred stock in AXIM Biotechnologies<\/a> (OTC BB: AXIM), a cutting-edge biotechnology innovator.<\/p>\n

Stuart W. Titus, PhD, President and CEO of Medical Marijuana Inc. mentions: \u201cWe are extremely excited to announce our strategic ownership interest in AXIM Biotech and explain to MJNA\u2019s shareholders some of the important innovations that Dr. Anastassov and the AXIM team are focused on. AXIM Biotech\u2019s recent announcements include hemp-based innovations that provide consumers a wide variety of new options worldwide.\u201d<\/p>\n

AXIM Biotech<\/a> is a unique biotechnology company focused on global research, development and production of pharmaceutical, food, nutraceutical and cosmetic products as well as biofuels derived from cannabinoids. AXIM Biotech is focusing its efforts on unique proprietary mechanisms for the delivery of cannabinoids (e.g. CBD, CBG, etc.).<\/p>\n

George E. Anastassov, MD, DDS, MBA and CEO of AXIM Biotech states, \u201cAXIM is a unique hemp-derived biosciences corporation where the responsibility for environmental protection and conservation meets the passion for development of innovative biotechnological applications for problems for which there are currently no solutions. \u00a0The cannabis plant provides ample opportunity for innovative, sometimes revolutionary products. \u00a0AXIM has realized the vast potential in oral health products based on cannabinoids, in particular CBG, and has filed intellectual property applications to protect its numerous IP.\u201d<\/p>\n

AXIM Biotech recently announced that it is the exclusive license recipient<\/a> to the world\u2019s first controlled-release cannabinoid chewing gum. \u00a0This opens two markets for product development and distribution: food with CanChew Plus\u00ae and pharmaceutical with MedChew RX\u2122, which is undergoing clinical trials in preparation for registration with FDA and EMA. \u00a0The Company also recently unveiled the world\u2019s first oral care and cosmetic lines<\/a>, ORAXIMAX\u2122 and RENECANN\u2122, containing cannabigerol (CBG).<\/p>\n

The global pharmaceutical market is reported to be potentially worth nearly $1.6 trillion by 2020<\/a>. AXIM Biotech intends to develop innovative pharmaceutical delivery systems and API (active pharmaceutical ingredients) for treatment of conditions such as Parkinson\u2019s disease, Alzheimer\u2019s disease, ADHD (attention deficit hyperactivity disorder), PTSD, autism, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBS, IBD, Crohn\u2019s disease and more. \u00a0All of these efforts are based on proprietary IP.<\/p>\n

Additional markets where AXIM Biotech intends to play a significant role are:<\/p>\n